In a research report issued today, Oppenheimer analyst Rohit Vanjani maintained an Outperform rating on OvaScience Inc (NASDAQ:OVAS) with a $60 price target, after hosting investor meetings with OvaScience’s management. OvaScience shares are currently trading at $28, down $1.59 or 5.37%.

Vanjani noted, “Much of the focus of the meetings centered around the data presented at SRI, and we believe the meetings helped in explaining that data. The shares have been weak for the past two days, down ~16% (vs. S&P500 +0.5%) following a report published by the Southern Investigative Reporting Foundation and circulated broadly. We believe the SIRF report has a number of inaccuracies and continue to view any weakness in OVAS as a buying opportunity.”

Furthermore, “Management noted that both patient and physician inquiries have ticked up since the SRI meeting. Further, the offering clinics are using the physician posters presented at SRI as well as the case studies featuring patient experiences/results in discussions for new AUGMENT consultations.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Rohit Vanjani has a total average return of 45.8% and a 80.8% success rate. Vanjani has a -4.0% average return when recommending OVAS, and is ranked #10 out of 3569 analysts.

OVAS Chart